Meropenem Actavis

Meropenem, the active ingredient in Meropenem Actavis, is a carbapenem antibiotic presented as an injection for intravenous use. It treats severe bacterial infections such as complicated intra‑abdominal infections, complicated urinary tract infections, nosocomial pneumonia, septicemia and meningitis in hospitalized patients.

GNH USA supplies Meropenem Actavis as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres, oncology centres, pharmacies and clinics worldwide.

Meropenem Actavis is a broad‑spectrum carbapenem used for serious bacterial infections in the hospital setting.

Complicated intra‑abdominal infections: achieves clinical cure by eradicating mixed aerobic and anaerobic pathogens. Complicated urinary tract infections: eliminates resistant Gram‑negative organisms to resolve infection. Nosocomial pneumonia: provides rapid bacterial clearance in ventilated patients. Septicemia: controls bloodstream infection caused by susceptible bacteria. Meningitis: penetrates the cerebrospinal fluid to treat bacterial meningitis.

Adverse reactions may occur with any antimicrobial therapy and should be monitored.

Common Side Effects: - Nausea or vomiting - Diarrhea, including mild colitis - Headache - Rash or mild pruritus at the infusion site - Transient elevation of liver enzymes - Infusion‑related phlebitis

Serious or Rare Side Effects: - Seizures, especially in patients with renal impairment or CNS disease - Severe allergic reactions such as anaphylaxis or Stevens‑Johnson syndrome - Clostridioides difficile‑associated colitis - Acute renal failure or worsening of existing renal dysfunction - Hepatotoxicity with marked transaminase elevation - Hemolytic anemia or thrombocytopenia

Meropenem should be used with careful clinical assessment and monitoring.

Renal function: adjust dose in patients with impaired renal clearance. Allergy history: avoid in individuals with known hypersensitivity to carbapenems or other β‑lactams. Seizure risk: monitor neurologic status, especially in patients with CNS disorders. Concomitant antibiotics: evaluate for additive toxicity when combined with other nephrotoxic agents. Pregnancy and lactation: use only if potential benefit justifies potential risk. Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Meropenem may interact with several medicines; monitoring is advised.

Major Interactions (Avoid): - Valproic acid: meropenem can lower valproate concentrations, risking seizure breakthrough. - Cisplatin or other nephrotoxic agents: increased risk of renal toxicity. - Probenecid: may raise meropenem plasma levels, enhancing toxicity. - Live vaccines: concurrent use can reduce vaccine efficacy. - Other β‑lactam antibiotics: potential for antagonistic effects.

Moderate Interactions (Monitor Closely): - Loop diuretics: monitor electrolytes and renal function. - Aminoglycosides: watch for additive nephrotoxicity. - Warfarin: may affect INR, requiring coagulation monitoring.